A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Completed

Conditions studied: Multiple Sclerosis, Relapsing-Remitting

In brief

The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The secondary objectives of the study also aim to characterize the participant's decision-making process to get the treatment; the burden of treatment, characterization of the study population, assessment of the quality of life (QoL), and fatigue dimension.

Key facts

Study ID

NCT06127095

Run by

Biogen

People needed

474

Starts

2023-11-24

Expected to finish

2024-11-28

Last updated by the study team

2024-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants diagnosed with RRMS and followed by a neurologist in France.

You may not qualify if…

• Lack of literacy
• Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Where it is running

• Biogen — Cambridge, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.